The merger, approved earlier by the boards of both companies, will combine Quality Care India (Transferor Company) with Aster DM Healthcare (Transferee Company) under Sections 230-232 of the Companies Act, 2013. The scheme is also subject to regulatory and statutory approvals, including the consent of shareholders and creditors of both companies, as per applicable laws.
This development follows Aster DM Healthcare’s earlier filing on November 29, 2024, regarding board approval of the scheme, and aligns with SEBI Listing Regulations, including Regulation 30 and Regulation 37, as well as the SEBI Master Circular on Schemes of Arrangement by listed entities.
Also Read: Aster DM Healthcare eyes further pledge reduction, targets strong growth post-merger
Aster DM Healthcare had acquired the stake in Quality Care India from BCP Asia II TopCo IV Pte Ltd (BCP) and Centella Mauritius Holdings Limited (Centella) through a share swap ahead of Quality Care India. QCIL's merger with Aster DM Healthcare was announced in November 2024.
The transaction was completed by acquiring 1,90,46,028 equity shares of QCIL by Aster DM Healthcare from BCP and TPG for a value of Rs 849.13 crore, Aster DM Healthcare said in a statement. As the discharge of the total purchase consideration payable, Aster has allotted 1,86,07,969 shares (face value Rs 10 each) to BCP and Centella, it added.
The merged entity — Aster DM Quality Care — will be jointly controlled by Aster Promoters and BCP and bring together the strengths of two leading healthcare providers with a common vision of expanding access to medical care across the country, it added.
Also Read: Aster DM Healthcare swings to profit in Q4; EBITDA rises 20% YoY
Shares of Aster DM Healthcare Ltd ended at ₹672.30, up by ₹27.10, or 4.20%, on the BSE.